Claims:

15

- 1. A compound comprising a peptidic vector and at least one fluorescein dye, wherein the peptidic vector
- comprises the amino acid sequence X_3 -G-D, wherein the peptidic vector and the fluorescein dyes are coupled, and wherein

 X_3 represents arginine, N-methylarginine or an arginine mimetic,

- 10 G represents glycine,
 - D represents aspartic acid,

or a physiologically acceptable salt thereof.

2. A compound as claimed in claim 1 given by formula I,

$$R_a-C (=0)-X_1-X_2-X_3-G-D-X_4-X_5-X_6-X_7$$
(I)

comprising two cyclising bridges,

wherein X_3 , G and D are defined as in claim 1, and wherein

 R_a represents $-(CH_2)_n$ - or $-(CH_2)_n$ - C_6H_4 - forming a bridge to either X_2 , X_4 or X_6 , wherein

n represents a positive integer from 1 to 10, and

X₁ represents a bond or 1, 2, 3, 4 or 5 amino acid residues, wherein one amino acid residue is optionally functionalised with a spacer moiety, or said amino acid residue possesses a functional side-chain such as an acid or amine group,

 X_2 and X_4 represent independently amino acid residues capable of forming a cyclising bridge,

 X_5 represents a hydrophobic amino acid or derivatives thereof, and

 X_6 represents an amino acid residue capable of forming a cyclising bridge, and

 X_7 represents a spacer or biomodifier moiety or is absent, and,

the compound further comprising at least one group Z, representing a fluorescein dye, linked to one or more of the groups X_1 , X_6 or X_7 optionally via a spacer group.

3. A compound as claimed in claim 2 selected from one of the formulas;

15

20

25

$$W_1 - Z$$
 $R_a - C (=0) - X_1 - X_2 - X_3 - G - D - X_4 - X_5 - X_6 - X_7 - Z_5$
 CH_2
 CH_2
 CH_3
 CH_4
 CH_5
 CH_5

(IV)

wherein R_a , X_1 , X_3 , G, D, X_5 , and X_7 are as defined in claims 1 and 2 and wherein

 X_2 , X_4 and X_6 represent amino acid residues capable of forming a disulphide or a thioether bond,

10 W₁ is a spacer moiety or is absent,

h is a positive integer 1 or 2,

and wherein at least one of the Z groups is present representing a fluorescein dye.

- 4. A compound of formula III as claimed in claim 3 wherein R_a represents -(CH_2)-.
- 20 5. A compound of formula III as claimed in any of claims 3 or 4 wherein X₁ represents an amino acid residue with a functional side-chain such as an acid or amine group, the amino acid being selected from aspartic acid, lysine, glutamic acid, homolysine or a diaminoalcylic acid or derivatives thereof.
 - 6. A compound of formula III as claimed in any of claims 3 to 5 wherein X_2 , X_4 and X_6 independently represent a cysteine or homocysteine residue.

- 7. A compound of formula III as claimed in any of claims 3 to 6 wherein X_3 represents arginine.
- 8. A compound of formula III as claimed in any of claims 3 to 7 wherein X_5 represents phenylalanine, tyrosine, a 3-iodo-tyrosine or naphthylalanine.
- 9. A compound of formula III as claimed in any of claims 3 to 8 wherein X₇ comprises 1-10 units of a monodisperse PEG building block or is absent.
 - 10. A pharmaceutical composition comprising an effective amount of a compound of any of the previous claims, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents.
 - 11. Compounds of any of claims 1 to 9 for use as an optical imaging contrast agent.

15

- 12. Use of a compound as claimed in any one of claims 1 to 9 in the manufacture of an optical imaging contrast agent for use in a method of diagnosis involving administering said contrast agent to a human or animal body and generating an image of at least part of said body.
- 13. A method of generating images of a human or animal body by optical imaging involving administering a contrast agent to said body, and generating an image of at least a part of said body to which said contrast agent has distributed, characterized in that said contrast agent comprises a compound as claimed in any one of claims 1 to 9.